China Universal Asset Management Co. Ltd. Raises Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

China Universal Asset Management Co. Ltd. grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 64.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,572 shares of the biopharmaceutical company’s stock after buying an additional 5,704 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Xenon Pharmaceuticals were worth $574,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the company. Driehaus Capital Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 2.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock worth $172,315,000 after purchasing an additional 97,732 shares during the period. Capital International Investors lifted its holdings in Xenon Pharmaceuticals by 0.8% during the first quarter. Capital International Investors now owns 2,475,859 shares of the biopharmaceutical company’s stock worth $106,586,000 after buying an additional 20,176 shares during the period. Affinity Asset Advisors LLC increased its position in shares of Xenon Pharmaceuticals by 18.7% during the second quarter. Affinity Asset Advisors LLC now owns 994,227 shares of the biopharmaceutical company’s stock worth $38,765,000 after purchasing an additional 156,840 shares in the last quarter. Lord Abbett & CO. LLC increased its position in shares of Xenon Pharmaceuticals by 24.7% during the first quarter. Lord Abbett & CO. LLC now owns 895,196 shares of the biopharmaceutical company’s stock worth $38,539,000 after purchasing an additional 177,224 shares in the last quarter. Finally, Samlyn Capital LLC increased its position in shares of Xenon Pharmaceuticals by 61.5% during the second quarter. Samlyn Capital LLC now owns 639,685 shares of the biopharmaceutical company’s stock worth $24,941,000 after purchasing an additional 243,489 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Trading Up 0.1 %

XENE opened at $41.78 on Wednesday. The stock’s 50-day moving average price is $40.48 and its 200 day moving average price is $40.15. Xenon Pharmaceuticals Inc. has a 12-month low of $27.99 and a 12-month high of $50.99. The firm has a market cap of $3.15 billion, a price-to-earnings ratio of -15.42 and a beta of 1.25.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same period in the previous year, the business earned ($0.72) earnings per share. On average, research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analyst Ratings Changes

XENE has been the topic of several research reports. Raymond James reissued an “outperform” rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Xenon Pharmaceuticals in a research note on Friday, August 9th. Wedbush decreased their price target on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd. Finally, HC Wainwright initiated coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, October 1st. They issued a “buy” rating and a $53.00 target price on the stock. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $57.45.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.